TheraCellix™ welcomed a visit from Indonesia’s National Agency of Drug and Food Control (Badan Pengawas Obat dan Makanan / BPOM) on 30 April 2026 as part of the company’s preparation for Good Manufacturing Practice (GMP/CPOB) certification prior to the commencement of stem cell manufacturing activities.
The visit reviewed the readiness of the company’s facilities, manufacturing arrangements, and quality management systems prior to GMP certification. It also supported TheraCellix™ in identifying key considerations for establishing appropriate manufacturing practices prior to the commencement of production activities.
As a stem cell manufacturing company preparing for production, TheraCellix™ recognizes the importance of establishing a controlled manufacturing environment, robust quality systems, and appropriate procedures to support product quality, consistency, and safety.
TheraCellix™ remains committed to strengthening its operational readiness and quality management systems in preparation for GMP certification and future manufacturing activities, with a focus on regulatory compliance and adherence to applicable quality and safety standards.
